#CBIO Crescent Biopharma Announces Grants of Inducement Awards
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-lg6t62t6nu1m.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-lg6t62t6nu1m.html?utm_source=stocktitan-bluesky&utm_medium=social
Crescent Biopharma Announces Grants of Inducement Awards
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 3, 2026 at 9:15 PM
#CBIO Crescent Biopharma Announces Grants of Inducement Awards
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-lg6t62t6nu1m.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-lg6t62t6nu1m.html?utm_source=stocktitan-bluesky&utm_medium=social
#CBIO Crescent Biopharma to Present at November Investor Conferences
https://www.stocktitan.net/news/CBIO/crescent-biopharma-to-present-at-november-investor-i5ls1t43micz.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-to-present-at-november-investor-i5ls1t43micz.html?utm_source=stocktitan-bluesky&utm_medium=social
www.stocktitan.net
November 2, 2026 at 12:30 PM
#CBIO Crescent Biopharma to Present at November Investor Conferences
https://www.stocktitan.net/news/CBIO/crescent-biopharma-to-present-at-november-investor-i5ls1t43micz.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-to-present-at-november-investor-i5ls1t43micz.html?utm_source=stocktitan-bluesky&utm_medium=social
#$CBIO weekly close $13.48 (+5.1% w/w), below SMA50 $15.62 / below SMA200 $15.89, RSI 46.1. Range $11.78-$15.28.
CBIO Stock Hub: Crescent Biopharma News, Oncology Pipeline and Funding
www.merlintrader.com/crescent-bio...
CBIO Stock Hub: Crescent Biopharma News, Oncology Pipeline and Funding
www.merlintrader.com/crescent-bio...
CBIO Stock: Crescent Biopharma News
Crescent Biopharma stock news: oncology pipeline and funding, financial resources, milestones and the risks to execution and funding.
www.merlintrader.com
November 1, 2026 at 7:47 PM
#$CBIO weekly close $13.48 (+5.1% w/w), below SMA50 $15.62 / below SMA200 $15.89, RSI 46.1. Range $11.78-$15.28.
CBIO Stock Hub: Crescent Biopharma News, Oncology Pipeline and Funding
www.merlintrader.com/crescent-bio...
CBIO Stock Hub: Crescent Biopharma News, Oncology Pipeline and Funding
www.merlintrader.com/crescent-bio...
o que lo uses para informar: "estos son los derechos de los pasajeros " o " los retrasos x cbio climático se han incrementado en un xxx % en relación a" u otra información relevante. Tenemos derecho a exigir información relevante y no hojas parroquiales 🤬
October 26, 2026 at 10:49 PM
o que lo uses para informar: "estos son los derechos de los pasajeros " o " los retrasos x cbio climático se han incrementado en un xxx % en relación a" u otra información relevante. Tenemos derecho a exigir información relevante y no hojas parroquiales 🤬
Latest analyst update, October 19, 2026: An analyst maintained its $36 price target on Crescent Biopharma (a third-party opinion, not a recommendation). $CBIO
https://www.merlintrader.com/crescent-biopharma-cbio-stock-hub/
https://www.merlintrader.com/crescent-biopharma-cbio-stock-hub/
Crescent Biopharma $CBIO: CR-001, ADCs And Catalysts
Crescent Biopharma: CR-001 and ASCEND, the ADC pipeline, clinical catalysts, cash, licensing economics and dilution risks.
www.merlintrader.com
October 19, 2026 at 10:48 PM
Latest analyst update, October 19, 2026: An analyst maintained its $36 price target on Crescent Biopharma (a third-party opinion, not a recommendation). $CBIO
https://www.merlintrader.com/crescent-biopharma-cbio-stock-hub/
https://www.merlintrader.com/crescent-biopharma-cbio-stock-hub/
Latest company news, October 15, 2026: Crescent Biopharma is enrolling chemotherapy-combination cohorts in the Phase 1/2 ASCEND trial of CR-001, its PD-1 x VEGF bispecific, and plans more ADC combination studies. Initial CR-001 mono...
https://www.merlintrader.com/crescent-biopharma-cbio-stock-hub/
https://www.merlintrader.com/crescent-biopharma-cbio-stock-hub/
Crescent Biopharma $CBIO: CR-001, ADCs And Catalysts
Crescent Biopharma: CR-001 and ASCEND, the ADC pipeline, clinical catalysts, cash, licensing economics and dilution risks.
www.merlintrader.com
October 16, 2026 at 12:36 AM
Latest company news, October 15, 2026: Crescent Biopharma is enrolling chemotherapy-combination cohorts in the Phase 1/2 ASCEND trial of CR-001, its PD-1 x VEGF bispecific, and plans more ADC combination studies. Initial CR-001 mono...
https://www.merlintrader.com/crescent-biopharma-cbio-stock-hub/
https://www.merlintrader.com/crescent-biopharma-cbio-stock-hub/
🚨 $CBIO
On October 15, 2026, Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1/2 ASCEND trial, (ii...
On October 15, 2026, Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1/2 ASCEND trial, (ii...
SEC Filing: CBIO
Click to view the official SEC document.
www.sec.gov
October 15, 2026 at 8:26 PM
🚨 $CBIO
On October 15, 2026, Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1/2 ASCEND trial, (ii...
On October 15, 2026, Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1/2 ASCEND trial, (ii...
#CBIO Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Comb…
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-clinical-pipeline-momentum-including-sv8l3zwva7xw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-clinical-pipeline-momentum-including-sv8l3zwva7xw.html?utm_source=stocktitan-bluesky&utm_medium=social
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 15, 2026 at 8:15 PM
#CBIO Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Comb…
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-clinical-pipeline-momentum-including-sv8l3zwva7xw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-clinical-pipeline-momentum-including-sv8l3zwva7xw.html?utm_source=stocktitan-bluesky&utm_medium=social
CBIO Q2 2026 earnings: Revenue $0K · EPS $-0.74. Crescent Biopharma's Q2 2026 net loss widened 14% to $24.8M as R&D rose 60% on CR-001 trial and manufacturing costs; a $133.5M July raise lifts pro forma cash to $305.1M, runway into 2H 2028.
https://financialreportinsights.com/companies/cbio/2026/q2
https://financialreportinsights.com/companies/cbio/2026/q2
Crescent Biopharma, Inc. (CBIO) Q2 2026 Earnings: Revenue $0K
Crescent Biopharma's Q2 2026 net loss widened 14% to $24.8M as R&D rose 60% on CR-001 trial and manufacturing costs; a $133.5M July raise lifts pro forma cash to $305.1M, runway into 2H 2028.
financialreportinsights.com
October 14, 2026 at 11:10 PM
CBIO Q2 2026 earnings: Revenue $0K · EPS $-0.74. Crescent Biopharma's Q2 2026 net loss widened 14% to $24.8M as R&D rose 60% on CR-001 trial and manufacturing costs; a $133.5M July raise lifts pro forma cash to $305.1M, runway into 2H 2028.
https://financialreportinsights.com/companies/cbio/2026/q2
https://financialreportinsights.com/companies/cbio/2026/q2
#CBIO Crescent Biopharma Announces Grants of Inducement Awards
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-gy2ftnysro4b.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-gy2ftnysro4b.html?utm_source=stocktitan-bluesky&utm_medium=social
Crescent Biopharma Announces Grants of Inducement Awards
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 6, 2026 at 8:15 PM
#CBIO Crescent Biopharma Announces Grants of Inducement Awards
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-gy2ftnysro4b.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-gy2ftnysro4b.html?utm_source=stocktitan-bluesky&utm_medium=social
BUY $CBIO (CBIO.O) [Acquisition] @ 10:18:36Z
October 6, 2026 at 10:18 AM
BUY $CBIO (CBIO.O) [Acquisition] @ 10:18:36Z
BUY $CBIO (CBIO.O) [FDA] @ 11:30:02Z
October 5, 2026 at 11:30 AM
BUY $CBIO (CBIO.O) [FDA] @ 11:30:02Z
#CBIO Crescent Biopharma Announces Grants of Inducement Awards
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-p4summqxhcmg.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-p4summqxhcmg.html?utm_source=stocktitan-bluesky&utm_medium=social
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma (CBIO) approved inducement options covering 31,200 ordinary shares for two non-executive employees on September 24, 2026.The options have a 10-year term and a $14.24 exercise price, equal to the closing price of Crescent’s ordinary shares on Nasdaq on September 24. One-fourth of each employee’s options vest on the first anniversary of their start date, followed by one-forty-eighth monthly, subject to continued service through each vesting date. The awards were material to the employees’ acceptance of employment and are governed by Crescent’s amended 2025 Employment Inducement Incentive Award Plan.
www.stocktitan.net
September 25, 2026 at 8:15 PM
#CBIO Crescent Biopharma Announces Grants of Inducement Awards
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-p4summqxhcmg.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-grants-of-inducement-p4summqxhcmg.html?utm_source=stocktitan-bluesky&utm_medium=social
Five #CBIO executives—including the CFO, CMO, and Chief Scientific Officer—sold stock on the exact same day. Only $48K total, but nice calendar sync.
September 19, 2026 at 2:03 PM
Five #CBIO executives—including the CFO, CMO, and Chief Scientific Officer—sold stock on the exact same day. Only $48K total, but nice calendar sync.
🔴 #CBIO — Brumm Joshua T, Chief Executive Officer
SOLD: 7,837 shares @ $16.71
Total: $131K
Filed Sep 15, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/CBIO
#InsiderTrading #CBIO #StockMarket
SOLD: 7,837 shares @ $16.71
Total: $131K
Filed Sep 15, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/CBIO
#InsiderTrading #CBIO #StockMarket
FormDelta — Insider Trading Alerts
Brumm Joshua T just sold $131K in CBIO. Track all SEC Form 4 insider trades in real-time.
www.formdelta.com
September 18, 2026 at 8:03 PM
🔴 #CBIO — Brumm Joshua T, Chief Executive Officer
SOLD: 7,837 shares @ $16.71
Total: $131K
Filed Sep 15, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/CBIO
#InsiderTrading #CBIO #StockMarket
SOLD: 7,837 shares @ $16.71
Total: $131K
Filed Sep 15, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/CBIO
#InsiderTrading #CBIO #StockMarket
🚨 $CBIO
Bispham Barbara Harlin (See Remarks) sold 620 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Bispham Barbara Harlin (See Remarks) sold 620 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
SEC Filing: CBIO
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 8:04 PM
🚨 $CBIO
Bispham Barbara Harlin (See Remarks) sold 620 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Bispham Barbara Harlin (See Remarks) sold 620 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
🚨 $CBIO
Lynch Ryan (See Remarks) sold 240 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Lynch Ryan (See Remarks) sold 240 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
SEC Filing: CBIO
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 8:08 PM
🚨 $CBIO
Lynch Ryan (See Remarks) sold 240 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Lynch Ryan (See Remarks) sold 240 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
🚨 $CBIO
Pinkas Jan (Chief Scientific Officer) sold 658 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Pinkas Jan (Chief Scientific Officer) sold 658 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
SEC Filing: CBIO
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 8:07 PM
🚨 $CBIO
Pinkas Jan (Chief Scientific Officer) sold 658 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Pinkas Jan (Chief Scientific Officer) sold 658 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
🚨 $CBIO
McNeill Jonathan (President and COO) sold 4,570 shares at an average price of $16.9003 per common share. (Date: 2026-09-18)
McNeill Jonathan (President and COO) sold 4,570 shares at an average price of $16.9003 per common share. (Date: 2026-09-18)
SEC Filing: CBIO
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 8:04 PM
🚨 $CBIO
McNeill Jonathan (President and COO) sold 4,570 shares at an average price of $16.9003 per common share. (Date: 2026-09-18)
McNeill Jonathan (President and COO) sold 4,570 shares at an average price of $16.9003 per common share. (Date: 2026-09-18)
🚨 $CBIO
Im Ellie Eunkyung (Chief Medical Officer) sold 623 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Im Ellie Eunkyung (Chief Medical Officer) sold 623 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
SEC Filing: CBIO
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 8:06 PM
🚨 $CBIO
Im Ellie Eunkyung (Chief Medical Officer) sold 623 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Im Ellie Eunkyung (Chief Medical Officer) sold 623 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
🚨 $CBIO
Scalzo Richard William (Chief Financial Officer) sold 568 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Scalzo Richard William (Chief Financial Officer) sold 568 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
SEC Filing: CBIO
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 8:06 PM
🚨 $CBIO
Scalzo Richard William (Chief Financial Officer) sold 568 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
Scalzo Richard William (Chief Financial Officer) sold 568 shares at an average price of $17.9000 per common share. (Date: 2026-09-16)
🚨 $CBIO
Brumm Joshua T (Chief Executive Officer) sold 9,447 shares at an average price of $16.9128 per common share. (Date: 2026-09-18)
Brumm Joshua T (Chief Executive Officer) sold 9,447 shares at an average price of $16.9128 per common share. (Date: 2026-09-18)
SEC Filing: CBIO
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 8:04 PM
🚨 $CBIO
Brumm Joshua T (Chief Executive Officer) sold 9,447 shares at an average price of $16.9128 per common share. (Date: 2026-09-18)
Brumm Joshua T (Chief Executive Officer) sold 9,447 shares at an average price of $16.9128 per common share. (Date: 2026-09-18)
📄 #CBIO 10-Q — what changed
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited condensed consolidated finan
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited condensed consolidated finan
FormDelta — Insider Trading Alerts
What CRESCENT BIOPHARMA, INC. changed in their own words, quarter over quarter.
www.formdelta.com
September 18, 2026 at 8:03 PM
📄 #CBIO 10-Q — what changed
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited condensed consolidated finan
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited condensed consolidated finan
Crazy Japanese, bringing the news via an AI hamster and it is watched by over 133k Japanese.
Russia in Chaos!! 13 Million Facing Crisis!? Fuel Rationing in Leningrad Oblast!
www.youtube.com/watch?v=cBiO...
Russia in Chaos!! 13 Million Facing Crisis!? Fuel Rationing in Leningrad Oblast!
www.youtube.com/watch?v=cBiO...
2026/9/17 ロシア、大混乱!! 1300万人が生活危機!? レニングラード州で燃料販売制限！ 主要ディーゼル生産製油所50％が停止・減産の衝撃!!
YouTube video by ネット大衆紙「ブルーカラー」
www.youtube.com
September 17, 2026 at 2:09 PM
Crazy Japanese, bringing the news via an AI hamster and it is watched by over 133k Japanese.
Russia in Chaos!! 13 Million Facing Crisis!? Fuel Rationing in Leningrad Oblast!
www.youtube.com/watch?v=cBiO...
Russia in Chaos!! 13 Million Facing Crisis!? Fuel Rationing in Leningrad Oblast!
www.youtube.com/watch?v=cBiO...
📢 这一幕正在韩国医美圈真实上演。近期，韩国生物技术公司L&CBIO一款名为ElravieRe2O（以下称Re2O）的皮肤填充剂受到许多求美者追捧。Re2O即“returntoyour...
韩国“尸皮针”爆红：用死者皮肤做医美 你敢打吗？ | 文学城
www.wenxuecity.com
September 15, 2026 at 9:20 PM
📢 这一幕正在韩国医美圈真实上演。近期，韩国生物技术公司L&CBIO一款名为ElravieRe2O（以下称Re2O）的皮肤填充剂受到许多求美者追捧。Re2O即“returntoyour...